Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-04-03

FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Tyvaso (treprostinil) by United Therapeutics Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tyvaso (treprostinil)

Snippet

SUPPL AP for TYVASO (TREPROSTINIL)